These are the stocks posting the largest moves before the bell.Market Insiderread more
The Federal Reserve's expected interest rate cuts appears to have impacted J.P. Morgan's forecast for 2019 net interest income.Financeread more
J.P. Morgan chief Jamie Dimon praised the strength of the consumer after the largest U.S. bank posted strong second-quarter quarterly earnings release on Tuesday.Banksread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
KeyCorp said in an 8-K filing the fraud involves a "business customer" and was discovered "on or about" July 9.Banksread more
GE hasn't had a year this good during this millennium. After that massive surge, one trader is warning investors to stay away.Trading Nationread more
Johnson & Johnson's profit jumped 42% in the second quarter, with all three of the sprawling health-care company's businesses performing better than Wall Street expected.Health and Scienceread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Goldman Sachs reported second-quarter results that beat analysts' expectations Tuesday.Financeread more
Early Facebook investor and Trump supporter Peter Thiel weighed in on the Democrats taking on the president in 2020, saying he was "most scared' by Elizabeth Warren.2020 Electionsread more
Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
New Jersey filed a lawsuit Tuesday against the company that manufactures OxyContin, claiming a "direct link" between the state's opioid crisis and the firm's deceptive marketing practices. State Attorney General Christopher Porrino says the five-count lawsuit against Connecticut-based Purdue Pharma and two of its entities seeks undisclosed monetary damages for fraud and false claims.
Purdue Pharma issued a statement saying it "vigorously denies" the allegations. The company said it's deeply troubled by the opioid crisis and is dedicated to being part of the solution.
"As a company grounded in science, we must balance patient access to FDA-approved medicines, while working collaboratively to solve this public health challenge," it said.
The state claims Purdue exploited vulnerable new markets, including the elderly and the "opioid-naïve," to boost profits. It claims Purdue aggressively marketed opioids and duped doctors and the public into believing they should be the primary treatment option for chronic conditions — like arthritis and migraines — despite the lack of any studies examining treatment periods longer than 12 weeks.
"When we point the finger of blame for the deadly epidemic that has killed thousands in New Jersey, Purdue is in the bulls-eye of the target," Porrino said. "Today, my office took the first step toward holding them legally and financially responsible for their deception."
The suit includes three counts alleging violations of the state's Consumer Fraud Act and one count alleging violations of its False Claims Act. It also includes a charge of creating a public nuisance.
More than two dozen states, cities, and counties have sued the pharmaceutical companies.
New Jersey's Republican Gov. Chris Christie has made addiction services a priority in his final year in office. He also chairs President Donald Trump's commission on opioids.
Trump last week declared opioid abuse a national public health emergency and announced new steps to combat what he described as the worst drug crisis in U.S. history.
The U.S. Centers for Disease Control and Prevention found that, in 2015, drug overdoses killed more than 52,000 Americans. Most involved prescription opioids such as OxyContin or Vicodin or related illicit drugs such as heroin and fentanyl. People with addictions often switch among the drugs.